Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

It has been a banner year for biotech buyouts, and these are two of the prime targets.

That is a big risk investors take when trying to find the winners and losers within the biotech sector. While we made the ...

Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Shares of Profusa (PFSA) hit a record low on Thursday, crashing 28% after the biotech company announced its second reverse ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.

They have at least one thing in common: An exciting pipeline.